Skip to main content
Top
Published in: Virology Journal 1/2017

Open Access 01-12-2017 | Research

The dose of HBV genome contained plasmid has a great impact on HBV persistence in hydrodynamic injection mouse model

Authors: Lei Li, Sheng Li, Yun Zhou, Lu Yang, Di Zhou, Yan Yang, Mengji Lu, Dongliang Yang, Jingjiao Song

Published in: Virology Journal | Issue 1/2017

Login to get access

Abstract

Background

Hydrodynamic injection (HI) of hepatitis B virus (HBV) mouse model is an useful tool for HBV related research in vivo. However, only 40% of C57/BL6 mice injected with 10 μg HBV genome contained plasmid (pAAV-HBV1.2), serum HBsAg more than 6 months and none of the BALB/c mice injected with 10 μg pAAV-HBV1.2 plasmid DNA, serum HBsAg positive more than 4 weeks in the previous study.

Methods

In this study, C57/BL6 and BALB/c mice were hydrodynamic injected with different doses of pAAV-HBV1.2 plasmid DNA. HBV related serum markers were detected by ELISA. ALT levels in the serum were measured using full automated biochemistry analyzer. HBcAg positive cells in the liver were detected by immunohistochemical staining. The mRNA levels of IRF3, ISGs including ISG15, OAS, PKR and immune factors including IFNγ, TNFα, TGFβ, IL-6, IL-10, PDL1 in liver of the mice were quantified by qRT-PCR.

Results

The results showed that the mice injected with 100 μg high-concentration or 1 μg low-concentration of pAAV-HBV1.2 plasmid DNA did not excert dominant influence on HBV persistence. In contrast, injection of 5 μg intermediate-dose of pAAV-HBV1.2 plasmid DNA led to significant prolonged HBsAg expression and HBV persistence in both C57/BL6 (80% of the mice with HBsAg positive more than 6 months) and BALB/c (60% of the mice with HBsAg positive more than 3 months) mice. IFNγ was significant up-regulated in liver of the mice injected with 1 μg or 100 μg pAAV-HBV1.2 plasmid DNA. TNFα was up-regulated significantly in liver of the mice injected with 100 μg pAAV-HBV1.2 plasmid DNA. Moreover, PDL1 was significant up-regulated in liver of the mice injected with 5 μg pAAV-HBV1.2 plasmid DNA.

Conclusion

In this paper we demonstrated that, in the HBV HI mouse model, the concentration of injected pAAV-HBV1.2 plasmid DNA contributes to the diverse kinetics of HBsAg and HBeAg in the serum as well as HBcAg expression level in the liver, which then determined the HBV persisternce, while the antiviral factors IFNγ, TNFα as well as immune negative regulatory factor PDL1 play important roles on HBV persistence.
Literature
1.
go back to reference Araki K, Miyazaki J, Hino O, Tomita N, Chisaka O, et al. Expression and replication of hepatitis B virus genome in transgenic mice. Proc Natl Acad Sci U S A. 1989;86:207–11.CrossRefPubMedPubMedCentral Araki K, Miyazaki J, Hino O, Tomita N, Chisaka O, et al. Expression and replication of hepatitis B virus genome in transgenic mice. Proc Natl Acad Sci U S A. 1989;86:207–11.CrossRefPubMedPubMedCentral
2.
go back to reference Asabe S, Wieland SF, Chattopadhyay PK, Roederer M, Engle RE, et al. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol. 2009;83:9652–62.CrossRefPubMedPubMedCentral Asabe S, Wieland SF, Chattopadhyay PK, Roederer M, Engle RE, et al. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol. 2009;83:9652–62.CrossRefPubMedPubMedCentral
3.
go back to reference Bocher WO, Marcus H, Shakarchy R, Dekel B, Shouval D, et al. Antigen-specific B and T cells in human/mouse radiation chimera following immunization in vivo. Immunology. 1999;96:634–41.CrossRefPubMedPubMedCentral Bocher WO, Marcus H, Shakarchy R, Dekel B, Shouval D, et al. Antigen-specific B and T cells in human/mouse radiation chimera following immunization in vivo. Immunology. 1999;96:634–41.CrossRefPubMedPubMedCentral
4.
go back to reference Cobleigh MA, Buonocore L, Uprichard SL, Rose JK, Robek MD, et al. A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose. J Virol. 2010;84:7513–22.CrossRefPubMedPubMedCentral Cobleigh MA, Buonocore L, Uprichard SL, Rose JK, Robek MD, et al. A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose. J Virol. 2010;84:7513–22.CrossRefPubMedPubMedCentral
5.
go back to reference Dandri M, Burda MR, Torok E, Pollok JM, Iwanska A, et al. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology. 2001;33:981–8.CrossRefPubMed Dandri M, Burda MR, Torok E, Pollok JM, Iwanska A, et al. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology. 2001;33:981–8.CrossRefPubMed
6.
go back to reference Guidotti LG, Matzke B, Schaller H, Chisari FV. High-level hepatitis B virus replication in transgenic mice. J Virol. 1995;69:6158–69.PubMedPubMedCentral Guidotti LG, Matzke B, Schaller H, Chisari FV. High-level hepatitis B virus replication in transgenic mice. J Virol. 1995;69:6158–69.PubMedPubMedCentral
7.
go back to reference Huang LR, HL W, Chen PJ, Chen DS. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci U S A. 2006;103:17862–7.CrossRefPubMedPubMedCentral Huang LR, HL W, Chen PJ, Chen DS. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci U S A. 2006;103:17862–7.CrossRefPubMedPubMedCentral
8.
go back to reference Ilan E, Burakova T, Dagan S, Nussbaum O, Lubin I, et al. The hepatitis B virus-trimera mouse: a model for human HBV infection and evaluation of anti-HBV therapeutic agents. Hepatology. 1999;29:553–62.CrossRefPubMed Ilan E, Burakova T, Dagan S, Nussbaum O, Lubin I, et al. The hepatitis B virus-trimera mouse: a model for human HBV infection and evaluation of anti-HBV therapeutic agents. Hepatology. 1999;29:553–62.CrossRefPubMed
9.
go back to reference Larkin J, Clayton M, Sun B, Perchonock CE, Morgan JL, et al. Hepatitis B virus transgenic mouse model of chronic liver disease. Nat Med. 1999;5:907–12.CrossRefPubMed Larkin J, Clayton M, Sun B, Perchonock CE, Morgan JL, et al. Hepatitis B virus transgenic mouse model of chronic liver disease. Nat Med. 1999;5:907–12.CrossRefPubMed
10.
go back to reference Lin YJ, Huang LR, Yang HC, Tzeng HT, Hsu PN, et al. Hepatitis B virus core antigen determines viral persistence in a C57BL/6 mouse model. Proc Natl Acad Sci U S A. 2010;107:9340–5.CrossRefPubMedPubMedCentral Lin YJ, Huang LR, Yang HC, Tzeng HT, Hsu PN, et al. Hepatitis B virus core antigen determines viral persistence in a C57BL/6 mouse model. Proc Natl Acad Sci U S A. 2010;107:9340–5.CrossRefPubMedPubMedCentral
11.
go back to reference Lu M, Isogawa M, Xu Y, Hilken G. Immunization with the gene expressing woodchuck hepatitis virus nucleocapsid protein fused to cytotoxic-T-lymphocyte-associated antigen 4 leads to enhanced specific immune responses in mice and woodchucks. J Virol. 2005;79:6368–76.CrossRefPubMedPubMedCentral Lu M, Isogawa M, Xu Y, Hilken G. Immunization with the gene expressing woodchuck hepatitis virus nucleocapsid protein fused to cytotoxic-T-lymphocyte-associated antigen 4 leads to enhanced specific immune responses in mice and woodchucks. J Virol. 2005;79:6368–76.CrossRefPubMedPubMedCentral
12.
go back to reference Lu M, Yao X, Xu Y, Lorenz H, Dahmen U, et al. Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model. J Virol. 2008;82:2598–603.CrossRefPubMed Lu M, Yao X, Xu Y, Lorenz H, Dahmen U, et al. Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model. J Virol. 2008;82:2598–603.CrossRefPubMed
13.
go back to reference Mendy ME, Kaye S, van der Sande M, Rayco-Solon P, Waight PA, et al. Application of real-time PCR to quantify hepatitis B virus DNA in chronic carriers in the Gambia. Virol J. 2006;3:23.CrossRefPubMedPubMedCentral Mendy ME, Kaye S, van der Sande M, Rayco-Solon P, Waight PA, et al. Application of real-time PCR to quantify hepatitis B virus DNA in chronic carriers in the Gambia. Virol J. 2006;3:23.CrossRefPubMedPubMedCentral
14.
go back to reference Meng Z, Xu Y, Wu J, Tian Y, Kemper T, et al. Inhibition of hepatitis B virus gene expression and replication by endoribonuclease-prepared siRNA. J Virol Methods. 2008;150:27–33.CrossRefPubMed Meng Z, Xu Y, Wu J, Tian Y, Kemper T, et al. Inhibition of hepatitis B virus gene expression and replication by endoribonuclease-prepared siRNA. J Virol Methods. 2008;150:27–33.CrossRefPubMed
15.
go back to reference Moriyama T, Guilhot S, Klopchin K, Moss B, Pinkert CA, et al. Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science. 1990;248:361–4.CrossRefPubMed Moriyama T, Guilhot S, Klopchin K, Moss B, Pinkert CA, et al. Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science. 1990;248:361–4.CrossRefPubMed
16.
go back to reference Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212–9.CrossRefPubMed Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212–9.CrossRefPubMed
17.
go back to reference Song J, Zhou Y, Li S, Wang B, Zheng X, et al. Susceptibility of different hepatitis B virus isolates to interferon-alpha in a mouse model based on hydrodynamic injection. PLoS One. 2014;9:e90977.CrossRefPubMedPubMedCentral Song J, Zhou Y, Li S, Wang B, Zheng X, et al. Susceptibility of different hepatitis B virus isolates to interferon-alpha in a mouse model based on hydrodynamic injection. PLoS One. 2014;9:e90977.CrossRefPubMedPubMedCentral
18.
go back to reference Takehara T, Suzuki T, Ohkawa K, Hosui A, Jinushi M, et al. Viral covalently closed circular DNA in a non-transgenic mouse model for chronic hepatitis B virus replication. J Hepatol. 2006;44:267–74.CrossRefPubMed Takehara T, Suzuki T, Ohkawa K, Hosui A, Jinushi M, et al. Viral covalently closed circular DNA in a non-transgenic mouse model for chronic hepatitis B virus replication. J Hepatol. 2006;44:267–74.CrossRefPubMed
19.
go back to reference von Freyend MJ, Untergasser A, Arzberger S, Oberwinkler H, Drebber U, et al. Sequential control of hepatitis B virus in a mouse model of acute, self-resolving hepatitis B. J Viral Hepat. 2011;18:216–26.CrossRefPubMed von Freyend MJ, Untergasser A, Arzberger S, Oberwinkler H, Drebber U, et al. Sequential control of hepatitis B virus in a mouse model of acute, self-resolving hepatitis B. J Viral Hepat. 2011;18:216–26.CrossRefPubMed
20.
go back to reference Wu J, Lu M, Meng Z, Trippler M, Broering R, et al. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology. 2007;46:1769–78.CrossRefPubMed Wu J, Lu M, Meng Z, Trippler M, Broering R, et al. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology. 2007;46:1769–78.CrossRefPubMed
21.
go back to reference Yang PL, Althage A, Chung J, Maier H, Wieland S, et al. Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci U S A. 2010;107:798–802.CrossRefPubMed Yang PL, Althage A, Chung J, Maier H, Wieland S, et al. Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci U S A. 2010;107:798–802.CrossRefPubMed
22.
go back to reference Yin Y, Wu C, Song J, Wang J, Zhang E, et al. DNA immunization with fusion of CTLA-4 to hepatitis B virus (HBV) core protein enhanced Th2 type responses and cleared HBV with an accelerated kinetic. PLoS One. 2011;6:e22524.CrossRefPubMedPubMedCentral Yin Y, Wu C, Song J, Wang J, Zhang E, et al. DNA immunization with fusion of CTLA-4 to hepatitis B virus (HBV) core protein enhanced Th2 type responses and cleared HBV with an accelerated kinetic. PLoS One. 2011;6:e22524.CrossRefPubMedPubMedCentral
23.
go back to reference Zhang X, Zhang E, Ma Z, Pei R, Jiang M, et al. Modulation of hepatitis B virus replication and hepatocyte differentiation by MicroRNA-1. Hepatology. 2011;53:1476–85.CrossRefPubMed Zhang X, Zhang E, Ma Z, Pei R, Jiang M, et al. Modulation of hepatitis B virus replication and hepatocyte differentiation by MicroRNA-1. Hepatology. 2011;53:1476–85.CrossRefPubMed
Metadata
Title
The dose of HBV genome contained plasmid has a great impact on HBV persistence in hydrodynamic injection mouse model
Authors
Lei Li
Sheng Li
Yun Zhou
Lu Yang
Di Zhou
Yan Yang
Mengji Lu
Dongliang Yang
Jingjiao Song
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2017
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-017-0874-6

Other articles of this Issue 1/2017

Virology Journal 1/2017 Go to the issue